ProSomnus, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Leonard Liptak
- Full Time Employees
- 136
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5860 West Las Positas Boulevard Pleasanton CA United States of America 94588
- IPO Date
- Jul 28, 2021
- CIK
- 0001934064
- Website
- prosomnus.com
- Similar Companies
- Business
- ProSomnus, Inc. (OSA) designs, manufactures and markets precision intraoral medical devices for the treatment of obstructive sleep apnea (OSA), a condition affecting over one billion people worldwide and linked to comorbidities such as heart failure, stroke, hypertension, morbid obesity and type 2 diabetes; its core products include the FDA-cleared ProSomnus [IA], MicrO2 Sleep and Snore Devices, EVO line featuring EVO [PH] and the recently introduced EVO Guided, and next-generation devices with remote patient monitoring and intraoral oximetry capabilities. Headquartered in Pleasanton, California, and founded in 2016, the company serves dentists, sleep physicians and healthcare providers in the United States with a network exceeding 4,000 providers; its patented, patient-specific devices, produced via mass-customized manufacturing and digital milling, offer a non-invasive alternative to CPAP therapy with demonstrated superior efficacy, comfort, adherence and coverage by commercial insurance, Medicare, TRICARE and global government plans representing over 200 million lives. In 2024, ProSomnus filed for voluntary Chapter 11 bankruptcy to restructure its capital structure, reducing debt by approximately 60%, securing $20 million in new financing from existing investors including Cohanzick Management and CrossingBridge Advisors, transitioning to a private company, launching EVO Guided, achieving FDA registration for HWO2, introducing EVO Guided and earning a spot on the 2025 Inc. 5000 list of America's fastest-growing private companies for the fourth consecutive year.
Nyxoah to Host Investor Day in New York on July 8, 2026
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device
Inspire Medical: Sleeping Giant Awakens The OSA Implant Market, Initiating With A Buy
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results